Clinical trial Recruiting at 1 site Interventional

Long-term follow-up of the OPRA Implant System for upper limb amputees

Official title: A Multicenter, Multinational, Cohort Long-term Post-market Clinical Follow-up (PMCF) of the Safety and Efficacy of the Osseoanchored Prostheses for the Rehabilitation of Amputees (OPRA) Implant System When Used for Transhumeral Implantation in Amputee Patients

Run by Integrum · NCT06753110 · Data updated 2026-11-12

This study is testing how well the OPRA Implant System works and its safety for people who have lost their upper arm, by following them for many years after their treatment.

More Lower Limb Amputation trials

Quick facts

Study typeInterventional
SexAll
Enrollment70 (estimated)
SponsorIntegrum
Industry-sponsored
Locations6 sites (Melbourne, Victoria and 5 other locations)
StatusRecruiting
StartedFebruary 19, 2025
Main results expectedDecember 2025
Study endsMarch 2026
Registry record updatedJuly 3, 2025
Trial IDNCT06753110 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals with unilateral or bilateral upper limb amputations who have received the OPRA™ implant system before January 1, 2024.

Probably not a fit

Patients who have not consented to participate or those implanted with the e-OPRA system at the humeral level will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical investigation focuses on the long-term safety and efficacy of the OPRA™ Implant System used for transhumeral amputees. It is a multicenter, multinational, cohort study that will collect clinical data over a follow-up period ranging from 6 months to over 20 years. Participants will have been treated with the OPRA™ system prior to January 1, 2024, and will undergo assessments including patient-reported outcomes and functional tests, which can be completed in person or remotely. The study does not include a control group and aims to evaluate the performance of the implant in real-world settings.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the long-term effectiveness and safety of the OPRA™ Implant System, improving rehabilitation options for amputees.

How similar studies have gone: While there have been studies on osseoanchored prostheses, this specific long-term follow-up approach is relatively novel and untested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Unilateral or bilateral amputation
* OPRA™ implant system placed, and with S2 completed before 01-Jan-2024
* Having a minimum of 6 months of follow-up between S2 and enrolment

Exclusion Criteria:

* Subject not willing to consent
* Subject implanted with the e-OPRA system at the humeral level.

Where it's running

  • Medical University of Vienna Clinical laboratory for bionic limb reconstruction Währinger Gürtel 18-20 1090 Vienna, AUSTRIA
    Vienna, Austria
    Recruiting
  • The Alfred Hospital
    Melbourne, Victoria, Australia
    Not yet recruiting
  • University Hospital Ghent, UX Ghent
    Ghent, Belgium
    Not yet recruiting
  • Hannover Medical School
    Hanover, Germany
    Not yet recruiting
  • University Hospital Tübing
    Tübingen, Germany
    Not yet recruiting
  • University Medical Center Groningen
    Groningen, Netherlands
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.